Abstract:8058 Background: Bone metastases are common in patients with breast or prostate cancer and cause significant pain and skeletal morbidity. The need for radiation to bone to treat pain or prevent a fracture is a significant clinical event associated with disease progression and quality-of-life decline. Therefore, radiation to bone was included in the composite endpoints describing skeletal morbidity in recent clinical trials of zoledronic acid. Herein, a statistically robust nonparametric method was used to measure the cumulative burden of radiation to bone over the entire course of follow-up to evaluate the benefit of 4-mg zoledronic acid in patients with breast or prostate cancer enrolled in 2 large, randomized, phase III trials. We have previously reported by this method that zoledronic acid significantly reduces the overall cumulative incidence of skeletal complications compared with placebo or pamidronate (Pam) in these patient populations. Methods: These trials were GCP-compliant, and patients gave written informed consent. Patients received 4 mg zoledronic acid via 15-minute infusion every 3–4 weeks for 2 years. Comparators were 90 mg Pam via 2-hour infusion (breast cancer) or placebo (prostate cancer). Survival-adjusted multiple event analysis was performed via the methods of Cook et al. (Stat Med 1997;16;911–924) and Ghosh and Lin (Biometrics 2000;56:554–562). Results: In patients with breast cancer (n = 766), 4 mg zoledronic acid was superior to 90 mg Pam and significantly reduced the cumulative mean number of administrations of radiation to bone by 35.4% at 25 months (P = .003), adding to the benefit achieved with Pam. Similarly, in patients with prostate cancer, 4 mg zoledronic acid significantly reduced the cumulative mean number of administrations of radiation to bone by 33.2% compared with placebo at 24 months (P = .034). Conclusion: This new, robust method provides a simple graphic representation of the cumulative need for radiation therapy and reveals the significant reduction in need for radiation therapy achieved with zoledronic acid in breast or prostate cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Novartis (US)

Randomized, Multicenter, Double - Blind, Double - Imitative, Comparative Trial of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases in Cancer Patients

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

Clinical Comparative Study of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases Lung Cancer

A multicenter randomized, double-blind and double dim comparative studies on zoledronic acid and pamidronate disodium: Phase II trials from 12 centers for treating bone metastasis pain

Combined chemotherapy of zoledronic acid and pamidronate in the treatment of bone metastases from nonsmall cell lung cancer and the effects on pain stress and bone metabolic indices

The effect of zoledronic and pamidronate acid in treating bone pain in bone metastases of malignant tumor and its impact on serum calcium and phosphorus

A Clinical Study of Different Administration of Pamidronate in the Patients with Painful Bone Metastases Due to Lung Cancer

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients with Lung Cancer and Other Solid Tumors: a Phase III, Double-Blind, Randomized Trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

A Comparative Study of Samarium-153-Ethylenediaminetetramethylene Phosphonic Acid with Pamidronate Disodium in the Treatment of Patients with Painful Metastatic Bone Cancer

Long-term Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Nonsmall Cell Lung Carcinoma and Other Solid Tumors: a Randomized, Phase III, Double-Blind, Placebo-Controlled Trial.

Zoledronic Acid Reduces the Need for Radiation to Bone in Patients with Breast or Prostate Cancer Metastatic to Bone: A Survival-Adjusted Cumulative Incidence Analysis

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors.

Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

The Comparison of Radionuclide Therapy With 153Sm-EDTMP and Chemotherapy With Pamidronate Disodium in the Patients With Painful Metastatic Bone Cancer

Efficacy of chemotherapy combined with pamidronate disodium in treatment of cancer bone metastasis

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

Effect of Metronomic Use of Zoledronic Acid (ZOL) on Antitumor and Antiosteoclastic Effects in Breast Cancer Patients with Bone Metastasis

Efficacy and Safety of Denosumab Versus Zoledronic acid in Suppressing Bone Metastases of Breast Cancer